GNI Group Ltd
3G6
Company Profile
Business description
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.
Contact
Shinjuku Park Tower
3-7-1 Nishi-Shinjuku
Shinjuku-ku
Tokyo163-1030
JPNT: +81 353263097
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,040
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
John Ternus, Apple’s hardware chief, will take up the role in September.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.40 | 50.80 | -0.56% |
| CAC 40 | 8,209.65 | 26.06 | -0.32% |
| DAX 40 | 24,223.33 | 47.54 | -0.20% |
| Dow JONES (US) | 49,149.38 | 293.18 | -0.59% |
| FTSE 100 | 10,492.30 | 5.79 | -0.06% |
| HKSE | 26,163.24 | 324.24 | -1.22% |
| NASDAQ | 24,259.96 | 144.43 | -0.59% |
| Nikkei 225 | 59,585.86 | 236.69 | 0.40% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,064.01 | 45.13 | -0.63% |
| S&P/ASX 200 | 8,843.60 | 53.20 | -0.60% |
| SSE Composite Index | 4,106.26 | 21.18 | 0.52% |